Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Business combinations (Tables)

3 Months Ended

Mar. 31, 2024


Consideration transferred:
Fair value of 357,429,306 ordinary shares issued	$	60,763
Fair value of replacement options and RSU-style options granted attributable to pre-combination service:		963
Purchase consideration	$	61,726

Identifiable assets acquired and liabilities assumed:

Assets acquired
Cash and cash equivalents	$	43,610
Restricted cash		1,654
Marketable securities - available-for-sale debt securities		39,532
Other current assets and prepaid expenses		6,029
Property, plant and equipment		2,712
Operating lease right-of-use assets		5,145
Intangible assets		58
Total assets acquired	$	98,740

Liabilities assumed
Accounts payable		(6,210)
Accrued expenses and other current liabilities		(4,537)
Operating lease liabilities, current		(1,974)
Operating lease liabilities, non-current		(2,244)
Total liabilities assumed	$	(14,965)

Net assets acquired and liabilities assumed	$	83,775


Gain on bargain purchase

Purchase consideration	$	(61,726)
Net assets acquired and liabilities assumed		83,775
Gain on bargain purchase	$	22,049

The Company incurred the following acquisition-related costs that were recognized as an expense in 2023:


	Three months ended		Total
	March 31,		acquisition-related
	2023		costs
Legal, professional and accounting fees	$	3,323	$	5,174
Bankers' fees		750		2,172
Total acquisition-related costs	$	4,073	$	7,346